A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BioNTech SE
BioNTech SE
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
OncoC4, Inc.
National Institutes of Health Clinical Center (CC)
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
Imugene Limited
AstraZeneca
National Institutes of Health Clinical Center (CC)
Cedars-Sinai Medical Center
University of Florida
DualityBio Inc.
Big Ten Cancer Research Consortium
Genfit
State Budget Public Health Institution Scientific Research Institute - Ochapovsky Regional Clinical Hospital